13F HOLDINGS REPORT
Caligan Partners LP
Quarter ended Q3 2024 · Filed November 14, 2024 · Accession 0001420506-24-002574
Total Value
$315.5M
Positions
12
Other Managers
0
Confidential Omitted
No
Holdings (12)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | LIQUIDIA CORPORATION | LQDA | 8,118,592 | $81.2M | 25.73% |
| 2 | VERONA PHARMA PLC | 925050106 | 1,436,878 | $41.3M | 13.10% |
| 3 | EXELIXIS INC | EXEL | 1,525,730 | $39.6M | 12.55% |
| 4 | EVOLUS INC | EOLS | 2,193,488 | $35.5M | 11.26% |
| 5 | ANIKA THERAPEUTICS INC | ANIK | 1,435,130 | $35.4M | 11.24% |
| 6 | AGIOS PHARMACEUTICALS INC | AGIO | 579,717 | $25.8M | 8.16% |
| 7 | BIOCRYST PHARMACEUTICALS INC | BCRX | 2,583,585 | $19.6M | 6.22% |
| 8 | Y-MABS THERAPEUTICS INC | 984241109 | 1,195,253 | $15.7M | 4.98% |
| 9 | MINERALYS THERAPEUTICS INC | MLYS | 981,155 | $11.9M | 3.77% |
| 10 | I MAB | NBP | 3,499,330 | $4.3M | 1.38% |
| 11 | ENANTA PHARMACEUTICALS INC | ENTA | 322,453 | $3.3M | 1.06% |
| 12 | OUTLOOK THERAPEUTICS INC | OTLK | 318,699 | $1.7M | 0.54% |